Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma

Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma

Background Autologous stem cell transplantation (ASCT) after induction therapy improves disease-free survival for patients with multiple myeloma (MM). While the goal of ASCT is to render a minimal disease state, it is also associated with eradication of immunosuppressive cells, and we hypothesize th...

Full description

Saved in:
Bibliographic Details
Main Authors: Seunghee Kim-Schulze, Sundar Jagannath, Sacha Gnjatic, Ajai Chari, Samir Parekh, Keren Osman, Selma Bekri, Hearn Jay Cho, David G Coffey, Adolfo Aleman, Simone Kats, Amishi Dhadwal, Donna Catamero
Format: Article
Language:English
Published: BMJ Publishing Group 2024-04-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/4/e008110.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items